11 610

Cited 0 times in

A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: a clinical and cognitive evaluation

Authors
 So-Hee Eun  ;  Heung Dong Kim  ;  Hee Jung Chung  ;  Hoon-Chul Kang  ;  Joon Soo Lee  ;  Joon Sik Kim  ;  Su Jeong You  ;  Han Ku Moon  ;  Young-Mock Lee  ;  Dong Wook Kim  ;  Eun Sook Suh  ;  Ji Yeon Kim  ;  Juneyoung Lee  ;  Baik-Lin Eun 
Citation
 SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.21(9) : 679-684, 2012 
Journal Title
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
ISSN
 1059-1311 
Issue Date
2012
MeSH
Administration, Oral ; Adolescent ; Carbamazepine/administration & dosage ; Carbamazepine/analogs & derivatives* ; Child ; Child, Preschool ; Cognition Disorders/diagnosis ; Cognition Disorders/drug therapy* ; Cognition Disorders/epidemiology* ; Epilepsies, Partial/diagnosis ; Epilepsies, Partial/drug therapy* ; Epilepsies, Partial/epidemiology* ; Female ; Follow-Up Studies ; Humans ; Male ; Prospective Studies ; Suspensions
Keywords
Oxcarbazepine ; Epilepsy ; Child ; Cognition ; Behavior
Abstract
PURPOSE: We conducted a prospective, multicenter, open label trial to evaluate the effectiveness of oxcarbazepine (OXC) oral suspension as monotherapy for children newly diagnosed with partial seizures.

METHODS: This trial included a two- to eight-week titration and stabilization period to achieve effective target doses and a 24-week maintenance phase. The primary outcome measure was the seizure-free rate over six months, while a secondary measure was the change in cognition and behavior from screening to the end of the maintenance phase. The effectiveness of OXC was compared in intellectually normal versus intellectually impaired children (intelligence quotient <70).

RESULTS: We enrolled 171 patients and analyzed 168 as the per-protocol (PP) group (3 patients had protocol violations). The mean age of the PP group was 8.4±2.7 years. The maintenance dose of OXC was 24.9±8.0mg/kg/day. Of the 168 patients included in the efficacy analysis, 122 (72.6%) completed the study and 94 (56.0%) became seizure-free after the OXC treatment. Comparing the efficacy of OXC for intellectually normal and intellectually impaired patients, 79 (56.8%) of the 139 intellectually normal patients and 15 (51.7%) of the 29 intellectually impaired patients became seizure-free (P=0.61). After treatment, intelligence scale scores improved in intellectually normal patients compared to the intellectually impaired children (P<0.05). Social problems quantified by behavior scales improved in intellectually impaired patients compared to intellectually normal children (P<0.05).

CONCLUSIONS: OXC is effective and well-tolerated as monotherapy in children with partial seizures. There was no difference in the effectiveness of OXC between intellectually normal and intellectually impaired children.
Full Text
http://www.sciencedirect.com/science/article/pii/S1059131112001847
DOI
22902287
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Hoon Chul(강훈철) ORCID logo https://orcid.org/0000-0002-3659-8847
Kim, Heung Dong(김흥동) ORCID logo https://orcid.org/0000-0002-8031-7336
Lee, Young Mock(이영목) ORCID logo https://orcid.org/0000-0002-5838-249X
Lee, Joon Soo(이준수) ORCID logo https://orcid.org/0000-0001-9036-9343
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91844
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links